PTGX
Price
$44.86
Change
-$1.30 (-2.82%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
2.81B
6 days until earnings call
TRVI
Price
$6.34
Change
+$0.07 (+1.12%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
586.86M
14 days until earnings call
Ad is loading...

PTGX vs TRVI

Header iconPTGX vs TRVI Comparison
Open Charts PTGX vs TRVIBanner chart's image
Protagonist Therapeutics
Price$44.86
Change-$1.30 (-2.82%)
Volume$11.19K
Capitalization2.81B
Trevi Therapeutics
Price$6.34
Change+$0.07 (+1.12%)
Volume$13.66K
Capitalization586.86M
PTGX vs TRVI Comparison Chart
Loading...
PTGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TRVI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PTGX vs. TRVI commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PTGX is a Buy and TRVI is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (PTGX: $46.18 vs. TRVI: $6.27)
Brand notoriety: PTGX and TRVI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PTGX: 101% vs. TRVI: 44%
Market capitalization -- PTGX: $2.81B vs. TRVI: $586.86M
PTGX [@Biotechnology] is valued at $2.81B. TRVI’s [@Biotechnology] market capitalization is $586.86M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PTGX’s FA Score shows that 1 FA rating(s) are green whileTRVI’s FA Score has 0 green FA rating(s).

  • PTGX’s FA Score: 1 green, 4 red.
  • TRVI’s FA Score: 0 green, 5 red.
According to our system of comparison, PTGX is a better buy in the long-term than TRVI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PTGX’s TA Score shows that 6 TA indicator(s) are bullish while TRVI’s TA Score has 3 bullish TA indicator(s).

  • PTGX’s TA Score: 6 bullish, 4 bearish.
  • TRVI’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, PTGX is a better buy in the short-term than TRVI.

Price Growth

PTGX (@Biotechnology) experienced а +0.83% price change this week, while TRVI (@Biotechnology) price change was +2.79% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.94%. For the same industry, the average monthly price growth was -5.37%, and the average quarterly price growth was -12.15%.

Reported Earning Dates

PTGX is expected to report earnings on Jul 31, 2025.

TRVI is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+7.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PTGX($2.81B) has a higher market cap than TRVI($587M). TRVI YTD gains are higher at: 52.184 vs. PTGX (19.637). PTGX has higher annual earnings (EBITDA): 256M vs. TRVI (-44.19M). PTGX has more cash in the bank: 419M vs. TRVI (65.5M). TRVI has less debt than PTGX: TRVI (1.11M) vs PTGX (10.9M). PTGX has higher revenues than TRVI: PTGX (434M) vs TRVI (0).
PTGXTRVIPTGX / TRVI
Capitalization2.81B587M479%
EBITDA256M-44.19M-579%
Gain YTD19.63752.18438%
P/E Ratio10.84N/A-
Revenue434M0-
Total Cash419M65.5M640%
Total Debt10.9M1.11M979%
FUNDAMENTALS RATINGS
PTGX vs TRVI: Fundamental Ratings
PTGX
TRVI
OUTLOOK RATING
1..100
666
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
58
Fair valued
PROFIT vs RISK RATING
1..100
3955
SMR RATING
1..100
1595
PRICE GROWTH RATING
1..100
4336
P/E GROWTH RATING
1..100
42100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TRVI's Valuation (58) in the Pharmaceuticals Major industry is in the same range as PTGX (62) in the Biotechnology industry. This means that TRVI’s stock grew similarly to PTGX’s over the last 12 months.

PTGX's Profit vs Risk Rating (39) in the Biotechnology industry is in the same range as TRVI (55) in the Pharmaceuticals Major industry. This means that PTGX’s stock grew similarly to TRVI’s over the last 12 months.

PTGX's SMR Rating (15) in the Biotechnology industry is significantly better than the same rating for TRVI (95) in the Pharmaceuticals Major industry. This means that PTGX’s stock grew significantly faster than TRVI’s over the last 12 months.

TRVI's Price Growth Rating (36) in the Pharmaceuticals Major industry is in the same range as PTGX (43) in the Biotechnology industry. This means that TRVI’s stock grew similarly to PTGX’s over the last 12 months.

PTGX's P/E Growth Rating (42) in the Biotechnology industry is somewhat better than the same rating for TRVI (100) in the Pharmaceuticals Major industry. This means that PTGX’s stock grew somewhat faster than TRVI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PTGXTRVI
RSI
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
85%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
81%
Declines
ODDS (%)
Bearish Trend 17 days ago
76%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
81%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
PTGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TRVI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IRSRX14.25N/A
N/A
Macquarie Real Estate Securities R
RWIHX61.17N/A
N/A
American Funds Capital World Gr&Inc R5E
SLGFX17.75N/A
N/A
SEI Large Cap Index F (SIMT)
MYSIX15.98N/A
N/A
Victory Trivalent International Sm-Cp Y
PHRCX17.97N/A
N/A
Virtus Duff & Phelps Real Estate Secs C

PTGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PTGX has been loosely correlated with MLYS. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if PTGX jumps, then MLYS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PTGX
1D Price
Change %
PTGX100%
+0.72%
MLYS - PTGX
48%
Loosely correlated
+2.42%
CKPT - PTGX
47%
Loosely correlated
N/A
TRVI - PTGX
43%
Loosely correlated
+3.29%
DNLI - PTGX
41%
Loosely correlated
+1.85%
ORMP - PTGX
37%
Loosely correlated
+0.66%
More

TRVI and

Correlation & Price change

A.I.dvisor indicates that over the last year, TRVI has been loosely correlated with PTGX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if TRVI jumps, then PTGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TRVI
1D Price
Change %
TRVI100%
+3.29%
PTGX - TRVI
43%
Loosely correlated
+0.72%
CKPT - TRVI
34%
Loosely correlated
N/A
MLYS - TRVI
31%
Poorly correlated
+2.42%
AURA - TRVI
31%
Poorly correlated
+0.88%
QURE - TRVI
30%
Poorly correlated
N/A
More